Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Omacor in SCN5A Mutation Long QT Syndrome (LQT3)
2009-011819-20Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Apr 2009
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of omega-3-acid triglycerides in Long QT Syndrome Type 3 (LQT3), sponsored by Pierre Fabre Laboratories. Primary endpoint: Change in QTcF interval at 6 weeks. Started Apr 2009; status: completed.
02
Drugs
omega-3-acid triglycerides
03
Conditions
Long QT Syndrome Type 3 (LQT3)
Beyond the preview
Go deeper on 2009-011819-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011819-20.